News

Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study

ADORED Study Update: Final Trial Participant Completes the ADORED Study. Day 672 Readout is Expected in Q1 2026.

Siolta Therapeutics is Awarded a $1.8M Phase II SBIR to Develop a Live Biotherapeutic for Recurrent Bacterial Vaginosis

Dr. Ricardo Valladares Discusses Infant Microbiome and Allergy Links with Alba Health

Siolta Therapeutics and Cowellnex Enter Joint Research Agreement

Nexilico and Siolta Therapeutics Enter Collaboration Agreement to Address Necrotizing Enterocolitis

Siolta Therapeutics is Awarded a Phase I SBIR to Develop an LBP for Prevention of Necrotizing Enterocolitis

Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development of STMC-103H for Allergic Disease Prevention

Siolta Therapeutics Doses First Newborn in Groundbreaking Phase 2 Trial of STMC-103H for the Prevention of Atopic Diseases